Bone Biologics Corp Stock Alpha and Beta Analysis
| BBLG Stock | USD 1.26 0.04 3.08% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Bone Biologics Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in Bone Biologics over a specified time horizon. Remember, high Bone Biologics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Bone Biologics' market risk premium analysis include:
Beta 1.56 | Alpha 0.76 | Risk 19.77 | Sharpe Ratio 0.0716 | Expected Return 1.41 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Bone |
Bone Biologics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Bone Biologics market risk premium is the additional return an investor will receive from holding Bone Biologics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Bone Biologics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Bone Biologics' performance over market.| α | 0.76 | β | 1.56 |
Bone Biologics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Bone Biologics' Buy-and-hold return. Our buy-and-hold chart shows how Bone Biologics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Bone Biologics Market Price Analysis
Market price analysis indicators help investors to evaluate how Bone Biologics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Bone Biologics shares will generate the highest return on investment. By understating and applying Bone Biologics stock market price indicators, traders can identify Bone Biologics position entry and exit signals to maximize returns.
Bone Biologics Return and Market Media
The median price of Bone Biologics for the period between Sat, Aug 31, 2024 and Fri, Nov 29, 2024 is 1.44 with a coefficient of variation of 23.43. The daily time series for the period is distributed with a sample standard deviation of 0.36, arithmetic mean of 1.56, and mean deviation of 0.31. The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Angle Siddhesh Rajendra of 30713 shares of Bone Biologics at 1.73 subject to Rule 16b-3 | 09/17/2024 |
2 | Acquisition by Gagnon Robert E. of 30713 shares of Bone Biologics at 1.73 subject to Rule 16b-3 | 09/27/2024 |
3 | Reviewing Bone Biologics NanoVibronix | 10/14/2024 |
4 | Insider Trading | 10/16/2024 |
About Bone Biologics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Bone or other stocks. Alpha measures the amount that position in Bone Biologics Corp has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Payables Turnover | 0.001341 | 0.001274 | Days Of Inventory On Hand | 368.2 | 327.29 |
Bone Biologics Upcoming Company Events
As portrayed in its financial statements, the presentation of Bone Biologics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bone Biologics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Bone Biologics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Bone Biologics. Please utilize our Beneish M Score to check the likelihood of Bone Biologics' management manipulating its earnings.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Bone Biologics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Bone Biologics Backtesting, Bone Biologics Valuation, Bone Biologics Correlation, Bone Biologics Hype Analysis, Bone Biologics Volatility, Bone Biologics History and analyze Bone Biologics Performance. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Bone Biologics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.